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Abstract
Objective: To investigate and compare the incidence of histopathological placental lesions in mild gestational
hyperglycemia, gestational diabetes and overt diabetes at term and preterm gestation.
Research design and methods: One-hundred-and-thirty-one placental samples were collected from Diabetes
mellitus (DM) positive screened patients. Two diagnostic tests, glycemic profile and 100 g oral glucose tolerance
test (OGTT) in parallel identified 4 groups normoglycemic, mild gestational hyperglycemia (MGH), gestational DM
(GDM) or overt DM (DM). Placental tissue specimens and sections from 4 groups were obtained by uniform
random sampling and stained with hematoxylin-eosin.
Results: Placentas from MGH group presented 17 types of histopathological change and higher rates of syncytial
nodes and endarteritis. GDM placentas presented only nine types of histopathological change, high rates of
dysmaturity, low rates of calcification and no syncytial nodes. Overt DM placentas showed 22 types of
histopathological change, 21 of which were present in the preterm period. There were histopathological similarities
between MGH and DM placentas, but the former exhibited a higher incidence of endarteritis, which has been
described as a “post-mortem” phenomenon.
Conclusion: Our results confirmed that the distinct placental changes associated with DM and MGH depend on
gestational period during which the diabetic insult occurs. It may reasonably be inferred that subclinical maternal
hyperglycemia during pregnancy, as showed in MGH group, is responsible for increased placental endarteritis, a
postmortem lesion in the live fetus.
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Introduction
The placenta is a fetal tissue that separates the maternal
and fetal circulations and plays a central metabolic role
in pregnancy. The placenta of diabetic women has
attracted much interest, primarily because it is thought
that placental damage may be partially responsible for
the high incidence of fetal complications in pregnancies
complicated by Diabetes mellitus [1]. Glucose is the
main nutrient that passes to the fetus by facilitated dif-
fusion. Thus, increased amounts of glucose may reach
the fetus by facilitated transport through the placenta
[2]. Therefore, adaptations in cells that are in contact
with maternal and fetal circulation may occur in
response to this abundant glucose supply [1].
At term, the placentas of diabetic mothers show a
number of variations when compared to placentas from
non-diabetic mothers. Placentas of diabetic mothers
tend to be heavier [3] and exhibit immaturity of villi [4].
However, the morphological and histopathological
changes in Diabetes mellitus placentas are inconsistent
and even somewhat controversial [1]. Upon reviewing
the literature, no clear picture of the effects of diabetes
on the placenta emerges, most likely because of the vari-
ety of confounding factors that need to be controlled,
such as type of diabetes, severity of disease, modality of
treatment and quality of glycemic control. An attempt
has been made to find a clinical-morphological correla-
tion not only for manifest Diabetes mellitus, but also for
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lism. The timing of departures from excellent glycemic
control is critical in placental development and may
affect diabetes-related changes in the placenta [5].
There is controversy regarding the risk of adverse out-
comes associated with types of maternal glucose intoler-
ance that are less severe than overt diabetes [6]. Rudge
used two parallel diagnostic tests, 100-g OGTT and
Glucose Profile (GP), to classify pregnant women. GP
measures maternal plasma glucose levels every two
hours, from 8:00 AM to 6:00 PM while a standard diet
of 2840 calories divided into five meals is given. A fast-
ing glucose level of 90 mg/dL and postprandial glucose
of 130 mg/dL are considered normal, and a single
abnormal value confirms hyperglycemia. The combina-
tion of normal 100-g OGTT with altered GP defined a
new group of pregnant women who show mild gesta-
tional hyperglycemia but do not present the criteria for
gestational Diabetes mellitus [7]. This group can still
present glucose-mediated macrosomia, perinatal mortal-
ity rates and adverse perinatal outcomes similar to those
with GDM [8-18]. Studies have shown that maternal
postprandial glucose concentration is the most impor-
tant determinant of fetal overgrowth [19,20]. These find-
ings demonstrate the constant risk for fetal morbidity
associated with increasing maternal glucose intolerance
in pregnancy [18,21].
It is not known if mild degrees of hyperglycemia are
associated with the same histopathological lesions as
GDM or if these lesions are still present in the preterm
period. An elevation in the incidence of apoptosis and
Bcl-2 in the placentas of mild gestational hyperglycemia
has been demonstrated [22]. Calderon et al. [23]
observed higher total area of placental terminal villi as
well as a number of small villi and villous vessels, sug-
gesting a structural adaptive response to hypoxia in the
placenta [1].
T h ed i a b e t i ce n v i r o n m e n tm a yh a v ep r o f o u n de f f e c t s
on placental development and functions [24]. Recently it
was proposed that these specific effects critically depend
on the time period of gestation when the insult of dia-
betic environment acts upon the placenta [25]. Some
placental alterations continue to occur despite improve-
ments in maternal glycemic control over the last dec-
ades, thus indicating that hyperglycemia is not the only
causal factor [26,27]. We hypothesized that histopatho-
logical placental lesions are similar in patients with a
wide range of glucose tolerance either in preterm or in
term. Thus, the aim of the present study was to investi-
gate and compare the incidence of histopathological
lesions in placentas in mild gestational hyperglycemia,
gestational diabetes and overt diabetes at term and pre-
term gestation.
2. Material and methods
2.1 Population
The Ethics Committee for Research of Botucatu Medical
School - Unesp (Brazil) approved all procedures. The
women in the study also formally consented to sample
collection and the study goals. The methods used were
previously by Ghidini and Salafia [28]. All placentas
were prospectively collected from non-anomalous, sin-
gleton, live-born infants delivered between 34 and 38
weeks over the last year. Gestational age was established
by date of last menstrual period or early ultrasono-
graphic assessment, and the placentas were classified as
term or preterm (< 37 weeks). Hospital charts were
reviewed to confirm that the diagnostic criteria were
met in all cases. Birth weight centiles were assigned
based on the standards of Lubchenko et al. [29].
Gestational diabetes was diagnosed according to the
American Diabetes Association (ADA) criteria [30] for
the 100 g oral glucose tolerance test (OGTT), and mild
gestational hyperglycemia was diagnosed by normal
OGTT and altered glycemic profile (GP) [7]. Altered GP
were considered when any two values are found or
exceed fasting glycemia 90 mg/dL and post-prandial 130
mg/dL. The diagnostic tests were performed between 24
and 26 weeks of gestation in all positive screened
patients [30]. Women presenting pre-gestational dia-
betes were included in overt diabetes group [31]. The
normoglycemic group included healthy mothers with
normal OGTT and normal glucose profile, delivered
vaginally healthy babies at term. For the achievement of
normoglycemia diabetic and mild gestational hyperglyce-
mic patients were treated by diet alone and if necessary,
by diet plus insulin
Glycemic control was assessed during pregnancy. Ade-
quate glycemic control during pregnancy was defined as
a glycemic mean of 120 mg/dl or less, and inadequate
control was defined as a glycemic mean higher than 120
mg/dl.
Placental tissues were taken immediately after delivery
from 131 pregnancies at Botucatu University Hospital -
Unesp, a tertiary care hospital in Brazil, and classified as
follows: mild gestational hyperglycemic (n = 34), gesta-
tional diabetic (n = 8), overt diabetes (n = 83) and nor-
moglycemic (n = 6). The placental pathology
examinations were performed following a standard pro-
tocol, and the same pathologist, who was blinded to the
clinical data, reviewed all slides.
Placental tissues samples were collected and dissected
from the central part of the placental bed and prepared
for histopathological analyses. The fragments were then
either immediately fixed in formalin, dehydrated in a
graded ethanol series and embedded in paraffin accord-
ing to a standard protocol, sectioned at 5 μma n d
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The overall morphology of the placenta was evaluated
under a light microscope. The placental histopathologi-
cal analyses were performed in a computerized image
system coupled to a photomicroscope by a digital cam-
era. From each slide, 10 fields were randomly selected.
Twenty-two histopathological changes [32] identified
in a pilot study were grouped according to etiopatho-
geny. Lesions of circulatory pathology included cystoid
degeneration, chorial edema, edema of the intima, inter-
stitial hemorrhage, congestion and subchorial infarction.
Lesions indicative of degeneration included villus
edema, villus or intervillus fibrosis, calcification and
focal hyaline degeneration. Lesions of proliferation
included dysmaturity, Hofbauer cell hyperplasia, chor-
ioangiosis and syncytial nodes. Lesions of inflammation
included villitis and focal amnionitis. Other lesions
included “phantom cells” or cell remnants, two vessels,
endarteritis, duplicate membrane and cord hemorrhage.
A semiquantitative lesion score of 0 -1 was assigned
based on absence or presence of histopathological
changes. The total of these scores was used to calculate
the total score within each group of pregnant women by
gestational age (term and preterm) and glycemic control
(optimal and non-optimal).
The (%) placental changes index (PCI) was calculated
using the following formula:
PCI (% ) =
Total score × 100
22 × n
where 22 was the number of histopathological changes
observed in the placentas of diabetic women in a pilot
study, and n the number of placentas evaluated in each
group.
Data are presented as means or percentages. The Chi-
square test (c
2), followed by the exact Fisher test, when
necessary, was used to compare histopathological
changes between groups. Unpaired Students t-test was
used to compare maternal glycemia mean values [33]. P
values of < 0.05 were considered significant.
Results
Table 1 displays the demographic and clinical character-
istics of the four groups. Women were compared consid-
ering maternal age. Maternal glycemic mean increased
progressively across the diagnostic groups. Mean new-
born weights were similar but prematurity was more pre-
valent in the overt DM compared to MGH group.
The placental histological changes grouped according
to etiopathogeny showed no significant differences
(Table 2). All 22 histopathological changes were present
in the placentas of the overt DM group, 21 of which
were already observed in preterm period. Some histo-
pathological changes were detected only in the placentas
of GDM women: chorial edema, intimal edema, Hof-
bauer cell hyperplasia and villitis. The placentas of the
GDM group presented only nine histopathological
changes and were characterized by absence of syncytial
nodes, dysmaturity and less calcification than the nor-
moglycemic group. The placentas of the MGH group
showed changes not detected in the placentas of normo-
glycemic group but present in diabetic women: cystoid
degeneration, dysmaturity, phantom cells, two vessels in
the umbilical cord, and endarteritis. The MGH group
presented 17 changes, 13 of which were detected during
the preterm and at term periods, these placentas showed
syncytial nodes and increased endarteritis. Subchorial
infarct and a duplicate membrane characterized the nor-
moglycemic placenta.
There were no significant differences in placental
changes index (PCI) among the four groups within cate-
gories of gestational age and glycemic control (Table 3).
Table 1 Demographic, obstetric and perinatal characteristics of the study population
Pregnant groups
Characteristics Normoglycemia MGH GDM Overt DM
Maternal age (years) 26.7
a 31.1
a 27.1
a 29.0
a
Maternal glycemic mean (mg/dl) 86.2
a 98.9
b 114.1
c 122.1
d
Newborns
Birth weight (grams) 3250
a 3194
a 3490
a 3180
a
Term 6 (100.0)
a 28 (82.3)
a 8 (100.0)
a 28 (33.7)
a
Preterm 0 6 (17.7)
a 0 55 (66.3)
b
LGA 1 (16.7) 4 (11.8) 2 (25.0) 23 (27.7)
AGA 5 (83.3) 28 (82.4) 6 (75.0) 55 (66.3)
SGA 0 2 (5.9) 0 5 (6.0)
Total number 6 34 8 83
Data presented as mean or number (%)
LGA: Large for Gestational Age; AGA: Adequate for Gestational Age; SGA: Small for Gestational Age
Values followed by different letters present significant statistically difference (p < 0.05)
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Our results show that placentas from MGH mothers
presented more syncytial nodes and endarteritis and
exhibited 17 of 22 histopathological changes. Recent stu-
dies suggest that endarteritis is a “post-mortem” lesion
[34,35]. According to these authors, this lesion is not
inflammatory and frequently results from thrombosis of
proximal vessels. This is a microangiopathy resembling
the glomerulopathy of hemolytic-uremic syndrome
either in etiology or in pathology. It does not represent
a specific entity but is a typical “post mortem” phenom-
enon [34]. Therefore, the higher endarteritis incidence
in the MGH placentas may explain the high perinatal
mortality rate detected in this population [7] and rein-
force the new large correlation between progressive and
continuous levels of maternal glycemia and adverse
maternal and perinatal outcomes [36]. It is also possible
that the higher incidence of endarteritis may have been
r e s p o n s i b l ef o rt h e1 7 . 7 %o fp r e m a t u r ed e l i v e r i e si n
these pregnancies. More studies are necessary to con-
firm this observation.
The glycemic index of food probably represents the
physiological basis for the hyperglycemic levels detected
in these patients. A mixed nutrient meal elicit a more
robust insulin response and may be more physiologic
measure of maternal hyperglycemia and subsequent
macrossomia [37]. Mild hyperglycemic exchanges
throughout the placenta are probably an answer to low
i n t r a u t e r i n eh y p o x i aa n dm a yb er e s p o n s i b l ef o rt h e
alterations associated with hypervascularization of the
terminal villous that were present in this organ [23].
Recently the Hapo Study (2008) identified a significant
correlation between all three maternal OGTT values
bellow those meeting of the exclusion criteria from dia-
betes study, and absolute and relative birth weight and
protocol-driven neonatal c-peptide and glucose values.
There is a quantitative relationship between levels of
maternal glycemia and adverse maternal and perinatal
Table 2 Number and percentage (%) of placental histopathological changes in women presenting normoglycemia,
mild gestational hyperglycemia, gestational diabetes mellitus and overt diabetes mellitus
Pregnant groups
Histopathological changes Normoglycemia MGH GDM Overt DM
Circulatory
Cystoid degeneration 0 1 (2.9) 1 (12.5) 3 (3.6)
Chorial edema 0 0 0 2 (2.4)
Intima edema 0 0 0 4 (4.8)
Interstitial hemorrhage 1 (16.7) 2 (5.9) 0 3 (4.8)
Congestion 2 (33.3) 17 (50.0) 3 (37.5) 52 (62.6)
Subchorial infarct * 2 (33.3)
a 3 (8.8)
b 0 3 (3.6)
b
Degenerative
Villus edema 1 (16.7) 7 (20.6) 3 (37.5) 18 (21.7)
Villus fibrosis 1 (16.7) 8 (23.5) 0 11 (13.2)
Intervillus fibrosis 3 (50.0) 28 (82.4) 6 (75.0) 65 (78.3)
Calcification * 4 (66.7)
a 15 (44.1)
a 1 (12.5)
b 42 (50.6)
a
Focal hyaline degeneration 4 (66.7) 28 (82.4) 6 (75.0) 71 (85.5)
Proliferative
Dysmaturity 0 5 (14.7) 3 (37.5) 8 (9.6)
Hofbauer hyperplasia 0 0 0 1 (1.2)
Chorioangiosis 1 (16.7) 4 (11.8) 0 7 (8.4)
Syncytial nodes 1 (16.7)
a 11 (32.4)
b 0 8 (9.6)
a
Inflammatory
Villitis 0 0 0 2 (2.4)
Focal amnionitis 1 (16.7) 4 (11.8) 1 (12.5) 7 (8.4)
Others
Phantom cells 0 2 (5.9) 0 1 (1.2)
Two vessels 0 1 (2.9) 0 3 (3.6)
Endarteritis 0 8 (23.5)
a 1 (12.5)
b 7 (8.4)
b
Duplicate membrane 2 (33.3)
a 0 0 1 (1.2)
b
Cord hemorrhage 3 (50.0) 5 (14.7) 0 14 (18.1)
Total number 6 34 8 83
Values followed by different letters present significant statistically difference (p < 0.05)
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continuous. It may reasonably be inferred that placental
alterations, specifically endarteritis as a post mortem
lesion and the presence of 17 from 22 histopathological
changes in the MGH group, with a subclinical maternal
hyperglycemia during pregnancy, which predisposes to
macrosomia and late fetal death. Maternal hyperinsuline-
mia in MGH that persists after delivery [38] is a possible
candidate mechanism to explain the high endarteritis
occurrence in MGH placenta since if it persists after
delivery and it could be present early in the next gesta-
tion. More studies are necessary to confirm this hypoth-
esis. Evers et al. [39] were surprised to find that
histological abnormalities of LGA-control placentas were
almost comparable to those of diabetic mothers. One
possible explanation is that the control women had
MGH, which could only be disproven with the repeated
measurement of normal glucose levels during pregnancy.
These authors did not submit their patients to glucose
profile, and they may be similar to the MGH group in
our study [7]. The increased maternal BMI in control
group this study [39] is also similar to the MGH group
[38]. Despite the improvement in maternal glycemic con-
trol in GDM mothers, 25% of their newborns were classi-
fied as LGA, and all of them were at term. This
population exhibited rates of LGA equivalent to those
observed by Rudge et al. [7] but perinatal mortality simi-
lar to the diabetic patients treated with insulin. The pla-
centas of GDM patients were characterized by a high
incidence of dysmaturity, low indices of calcification, and
absence of syncytial nodes, despite all newborns being
born at term. These changes were not statistically signifi-
cant but suggest delayed placental maturation. The
decreased incidence of calcification might explain the
delay in placental senescence observed by ultrasound in
gestational diabetic patients [40].
The overt DM mothers had a higher glycemic mean
during pregnancy, 27.7% prevalence of LGA and the
highest incidence of prematurity among the evaluated
groups. The placentas of these patients presented all
22 histopathological changes, 21 of which were already
present at preterm period. The early occurrence of
these histopathological changes may be a cause of the
higher perinatal mortality of diabetic mothers. How-
ever, paired studies are necessary to test this hypoth-
esis due to the different indications for optimum
timing of delivery, including worsening of maternal
condition, reduced insulin necessity, fetal hypoxia and
fetal pulmonary maturity. The results found in the
overt diabetic group confirmed the Desoye et al.’ pro-
position [25], where specific effects depends on the
time of gestation when the insult of diabetic environ-
ment acts upon the placenta. Studies of synchronized
placental changes with different indications for elective
preterm delivery may help to explain the non-signifi-
cant correlation between clinical aspects and placental
histopathology in diabetes.
In conclusion, our results confirmed that the distinct
placental changes associated with DM and MGH
depend on gestational period when the diabetic insult
occurs, and thus on the type of diabetes [24]. It may
reasonably be inferred that subclinical maternal hyper-
glycemia during pregnancy, as showed in MGH group is
responsible not only for adverse perinatal outcome
[7,36] but also for increased placental endarteritis, a
postmortem lesion in the live fetus.
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